论文部分内容阅读
本研究应用益气活血清脑汤联合高压氧治疗气虚血瘀型眩晕患者,观察其临床治疗效果。通过随机选取2013年1月到2015年6月我院接诊的气虚血瘀型眩晕患者80例,根据其临床治疗方式的不同随机均分为研究组和对照组,40例对照组患者通过西药盐酸氟桂利嗪联合高压氧进行治疗,40例研究组患者通过益气活血清脑汤联合高压氧进行治疗,对比两组患者临床治疗效果。结果表明研究组患者治疗后LVA以及两组患者治疗后BVA和BA均较治疗前显著提高,研究组LVA、BVA和BA各指标治疗后值显著高于对照组(p<0.05);研究组患者治疗后TC、LDLC和TG较治疗前显著改善(p<0.05),HDLC与治疗前相比无显著改善(p>0.05);对照组治疗后TC和LDLC较治疗前显著改善(p<0.05),HDLC与TG较治疗前无显著改善(p>0.05);研究组患者治疗后TC改善情况显著优于对照组患者(p<0.05);研究组总治疗有效率(95.00%)显著高于对照组(80.00%)(p<0.05)。因此,益气活血清脑汤联合高压氧治疗气虚血瘀型眩晕临床治疗效果显著,值得进行临床推广。
In this study, Yiqi Huoxue Qingnao soup combined hyperbaric oxygen treatment of Qi deficiency and blood stasis type of patients with vertigo, to observe the clinical effect. Eighty patients with Qi-deficiency and blood-stasis type vertigo admitted to our hospital from January 2013 to June 2015 were randomly divided into study group and control group according to the different clinical treatment methods. Forty patients in control group were treated with western medicine Flunarizine hydrochloride combined with hyperbaric oxygen therapy, 40 patients in the study group were treated with Yiqi Huoxuenao Decoction combined with hyperbaric oxygen to compare the clinical effects of the two groups. The results showed that the LVA and BA patients in study group were significantly higher than those before treatment after treatment, LVA, BVA and BA in study group were significantly higher than those in control group (p <0.05) After treatment TC, LDLC and TG were significantly improved (p <0.05), HDLC had no significant improvement compared with those before treatment (p> 0.05); TC and LDLC in the control group were significantly improved after treatment (p <0.05) (P> 0.05). The improvement of TC in study group was significantly better than that in control group (p <0.05). The total effective rate of study group (95.00%) was significantly higher than that of control group Group (80.00%) (p <0.05). Therefore, Yiqi Huoxue Qingnao soup combined with hyperbaric oxygen treatment of Qi deficiency and blood stasis type of vertigo clinical treatment effect is significant, worthy of clinical promotion.